Prognostic Value of

Autor: E. Quaquarini 1, 2, D. D'Ambrosio 3, F. Sottotetti 1, F. Gallivanone 4, M. Hodolic 5, 6, P. Baiardi 7, R. Palumbo 1, C. Vellani 8, C. Canevari 9, A. Bernardo 1, I. Castiglioni 4, C. Porta 10, G. Trifirò 8

Publikováno v: Contrast media & molecular imaging 2019 (2019): 4325946. doi:10.1155/2019/4325946
info:cnr-pdr/source/autori:E. Quaquarini 1,2, D. D'Ambrosio 3, F. Sottotetti 1, F. Gallivanone 4, M. Hodolic 5,6, P. Baiardi 7, R. Palumbo 1, C. Vellani 8, C. Canevari 9, A. Bernardo 1, I. Castiglioni 4, C. Porta 10,11 and G. Trifirò 8/titolo:Prognostic Value of 18F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel./doi:10.1155%2F2019%2F4325946/rivista:Contrast media & molecular imaging/anno:2019/pagina_da:4325946/pagina_a:/intervallo_pagine:4325946/volume:2019
Contrast Media & Molecular Imaging
Contrast Media & Molecular Imaging, Vol 2019 (2019)

Background and Aim. The availability of new treatments for metastatic castrate-resistant prostate cancer (mCRPC) patients increases the need for reliable biomarkers to help clinicians to choose the better sequence strategy. The aim of the present ret

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb575be297905f66cb25768e235ef502
https://pubmed.ncbi.nlm.nih.gov/31049043